(19) World Intellectual Property **Organization**

International Bureau





(43) International Publication Date 12 February 2004 (12.02.2004)

(10) International Publication Number WO 2004/012574 A3

(51) International Patent Classification⁷: A61K 38/00, C07K 5/00, 14/00, C12N 15/11

(21) International Application Number:

PCT/US2003/022241

(22) International Filing Date: 16 July 2003 (16.07.2003)

(25) Filing Language: English

English (26) Publication Language:

(30) Priority Data:

60/396,171 16 July 2002 (16.07.2002)

(71) Applicant: DELTAGEN PROTEOMICS INC. [US/US]; 615 Arapeen Drive, Suite 300, Salt Lake City, UT 84108 (US).

(72) Inventor: KAMB, Carl, Alexander; 696 Donner Hill Circle, Salt Lake City, UT 84108 (US).

(74) Agent: WILLIAMS, Joseph, A.; Marshall, Gerstein & Borun LLP, 6300 Sears Tower, 233 South Wacker Drive, Chicago, Il 60606 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 3 February 2005

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NEGATIVE SELECTIONS ASSAYS, AND COMPOSITIONS THEREOF

(57) Abstract: The present invention is directed to methods for performing negative selection assays leading to the identification of cytostatic or cytotoxic agents that cause a lethal phenotype. The invention is useful also for evaluation of conditional cytotoxicity and cell-specific cytotoxicity.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/22241

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K 38/00; C07K 5/00, 14/00; C12N 15/11 US CL : 512/2; 536/23.1; 530/300, 350			
According to International Patent Classification (IPC) or to both national classification and IPC			
B. FIELDS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols) U.S.: 512/2; 536/23.1; 530/300, 350			
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Please See Continuation Sheet			
C. DOCUMENTS CONSIDERED TO BE RELEVANT			
Category * Citation of document, with indication, where a		Relevant to claim No.	
	US 6,368,598 B1 (D'AMICO et al.) 09 April 2002 teaches SEQ ID NO :16 (note column 17), identical to instant SEQ ID NO :10.		
A 17), identical to instant SEQ ID NO :10.			
X Database NCBI (Bethesda, Maryland, USA) NCNI A	Database NCBI (Bethesda, Maryland, USA) NCNI Accession No. AF250306, WAN et al., 17 April 2001 teaches SEQ ID NO:12, and polynucleotide encoding SEQ ID NO:12.		
A ADRA et al. RhoGDIy: A GDP-dissociation inhibition	ADRA et al. RhoGDIy: A GDP-dissociation inhibitor for Rho proteins with preferential expression in brain and pancreas. Proc. Natl. Acad. Sci., U S A. 29 April 1997, Vol. 94,		
Further documents are listed in the continuation of Box C.	See patent family annex.		
* Special categories of cited documents:	"T" later document published after the inte date and not in conflict with the applic	ation but cited to understand the	
"A" document defining the general state of the art which is not considered to be of particular relevance	principle or theory underlying the inve	ntion	
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the considered novel or cannot be consider when the document is taken alone		
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the considered to involve an inventive step combined with one or more other such	when the document is	
"O" document referring to an oral disclosure, use, exhibition or other means	being obvious to a person skilled in the	e art	
"P" document published prior to the international filing date but later than the priority date claimed	"&" document member of the same patent family		
Date of the actual completion of the international search Date of mailing of the international search report			
20 October 2004 (20.10.2004)	Authorized officer		
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US Commissioner for Patents P.O. Box 1450	MISOOK YU, Ph.D.		
F.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230			

INTERNATIONAL SEARCH REPORT	
	PCT/US03/22241
an and an array of GELAD CITED IV.	
Continuation of B. FIELDS SEARCHED Item 3: Sequence databases, Dialog (155), West (USPT, DWPI) Search terms: SEQ ID NOs 4-13, inducing cytotoxicity, cancer therapy	
Search terms: SEQ ID NOS 4-13, inducing cytoloxicity, cancer therapy	

Form PCT/ISA/210 (second sheet) (July 1998)